Objective: To investigate the levels of expression of the sodium iodide symporter (NIS) and three differentiation markers (thyroglobulin (Tg), thyroid peroxidase (TPO) and thyrotrophin receptor (TSH-R)) in 35 patients with primary (n ¼ 31) or recurrent (n ¼ 4) papillary thyroid carcinoma, and to compare the findings with clinical data. Methods: We performed a multiplex semi-quantitative RT-PCR to analyse the relative levels of expression of Tg, TPO and TSH-R mRNAs, and a separate semi-quantitative RT-PCR for NIS mRNA. Results: Tg, TPO and TSH-R mRNAs were expressed in all the patients, whereas NIS mRNA was expressed in all but eight. Analysis of the expression of the differentiation markers in all patients showed a significant correlation among Tg, TPO and NIS. With regard to the relationship between the expression of each gene and the MACIS score, there was significant correlation only for the Tg gene (P < 0.05).
Introduction
Thyroid-specific proteins such as thyroglobulin (Tg), thyroid peroxidase (TPO) and thyrotrophin receptor (TSH-R), are regarded as differentiation markers of thyroid follicular cells (1) . When serum iodide is taken into thyrocytes, a sodium iodide symporter (NIS) is necessary (2) . Because of this phenomenon, NIS also is regarded as a differentiation marker that reflects the production of thyroid hormone. The differentiation markers (Tg, TPO and TSH-R) are also expressed in differentiated thyroid carcinomas (3) (4) (5) , which have been reported to have the ability to uptake iodide (6) . As a result, radioiodine therapy has come into common use in the treatment of recurrent or metastatic differentiated thyroid carcinomas (6) (7) (8) . Although the effect of this treatment can usually be predicted by using a tracer dose of isotopic iodide (9) , a discrepancy in accumulation has often been reported between the tracer and treatment doses in metastatic lesions (10, 11) . Some studies have reported the successful prediction of the clinical effect of radioiodine therapy or the presence of recurrent sites by measuring serum thyroglobulin in patients who had undergone total thyroidectomy (9, 11, 12) . However, the histological expression of other differentiation markers (Tg, thyroxine and tri-iodothyronine) in tumours has not proved to predict radioiodine uptake successfully (13) .
The sequence of human NIS messenger ribonucleic acid (NIS mRNA) was reported in 1996 (14) . Since this cloning of NIS mRNA, studies of the expression of NIS mRNA or protein have been undertaken. A more recent study found the protein and mRNA levels of NIS in papillary thyroid carcinomas to be greater than those in adjacent normal thyroid tissues (15) . However, varied expression of NIS, including no expression, has also been noted in papillary carcinomas (16) (17) (18) (19) . In the present study, we investigated the levels of expression of NIS and three other differentiation markers in papillary thyroid carcinomas and compared them with clinical findings. all of whom gave their informed consent to inclusion in the study. All the participants were euthyroid before operation, and none was taking any drugs before operation. All the patients with papillary carcinoma underwent TSH suppression therapy with a thyroxine drug after surgery. The serum TSH values of all four patients with recurrent papillary thyroid carcinoma were below the limit of detection (<0.05 mU/l). The recurrent sites were the cervical lymph nodes in all these four patients; and dissection of these lymph nodes was performed in all of them. For PCR controls, we used three snap-frozen tissues of normal adjacent thyroid obtained during operation from the patients with papillary carcinoma. The clinical stages of the primary carcinomas were determined according to the International Union against Cancer (UICC) classification (20) , and their MACIS scores were calculated according to the protocol of Hay et al. (21) .
RT-PCR
Total cellular RNA was extracted from microdissected snap-frozen tissues using the phenol-guanidineisothiocyanate method with Trizol (Gibco BRL, Gaithersburg, MD, USA) according to the manufacturer's protocol. The purity of the total RNA was assessed by the ratio of optical density 260 nm to 280 nm (acceptable values being between 1.6 and 1.9) and by the absence of bands corresponding to contaminating DNA in agarose electrophoresis (data not shown). One microgram total RNA and 20 pmol oligo dT primer in 12.5 ml diethyl pirocarbonate (DEPC)-treated water were heated to 70 ЊC for 2 min, followed by cooling on ice for 1 min. cDNA synthesis was initiated using 200 U recombinant Moloney-murine leukaemia virus reverse transcriptase (Clontech Lab. Inc., Palo Alto, CA, USA) under conditions recommended by the manufacturer, and the reaction was allowed to proceed at 42 ЊC for 60 min, when it was terminated by heating at 94 ЊC for 5 min and the cDNA diluted to a final volume of 100 ml by adding 80 ml DEPC-treated water. The oligonucleotide primers, including b-actin cDNA (22) , and the conditions for amplification of Tg cDNA (23) , TPO cDNA (24), TSH-R cDNA (25) and NIS cDNA (14) are shown in Table 1 and Fig. 1a . The primers were made from cDNA sequences. Three oligonucleotide primers of each gene except b-actin were made and we selected one primer set from each without interfering with the b-actin primer set (data not shown). The PCR was performed using a PC-960G microplate gradient thermal cycler A semi-quantitative multiplex RT-PCR in the same tube was designed to compare the RT-PCR products of the Tg, TPO and TSH-R genes with b-actin gene products to determine the relative levels of expression of the Tg, TPO and TSH-R mRNAs in these patients. To obtain a phase in which both the differentiation marker mRNAs and the b-actin mRNA would be amplified logarithmically (Fig. 1b) , each reaction of a semi-quantitative multiplex RT-PCR contained the same reagents described above, except for the addition of each primer with the primer of b-actin (Table 1) . We attempted to perform a semi-quantitative multiplex RT-PCR in the same tube, to detect the NIS mRNA, but we could not obtain reproducible results, and therefore we used a separate RT-PCR for the NIS and the b-actin mRNA (Table 1) . To determine the specificity of these RT-PCRs, we performed them three times and took the mean values of the three replications. Each RT-PCR product was demonstrated on 1.4% agarose gel stained with ethidium bromide. The bands of the positive film were scanned and the density and the width of each PCR product were measured using Quantity One software (pdi, New York, NY, USA) to calculate the ratio of each product of the Tg, TPO, TSH-R and NIS mRNAs to b-actin mRNA. We used adjacent normal thyroid tissues as positive controls. We also performed a PCR without cDNA, using each primer as a negative control. One negative control and three positive controls were included in every reaction. In addition, we evaluated the relationship between the relative rates in each patient and their clinical characteristics.
Statistical analysis
For statistical analysis, Mann-Whitney's U test and the Scheffé test were used as post hoc tests; Welch's t-test and Pearson's correlation coefficient test were also used. P < 0.05 was taken as significant.
Results

Clinical characteristics (Table 2)
Twenty-six (74.3%) of the 35 patients were women and nine (25.7%) were men. The mean age of the patients with primary papillary carcinoma was 52.26 years (range 20-74 years) and that of the patients with recurrent disease was 75 years (58-90 years). Six patients with primary papillary carcinoma showed extrathyroidal infiltration. There were 10 patients with stage 1, three patients with stage 2 and 18 patients with stage 3 carcinoma. The mean Ϯ S.D. tumour size and MACIS score were 2.53 Ϯ 1.7 cm and 5.32 Ϯ 1.2 respectively.
Levels of expression of Tg, TPO, TSH-R and NIS mRNA
The three differentiation markers, Tg, TPO, TSH-R mRNAs, were expressed in all patients. NIS mRNA was not expressed in eight of them (nos 12, 20, 24, 26, 28, 31, 32 and 33); Fig. 2 shows the findings in two of them (nos 26 and 28). In the patients with primary papillary carcinoma, the mean Ϯ S.D. values of the ratio relative to the b-actin gene were 1.7 Ϯ 0.84 (Tg), 0.46 Ϯ 0.19 (TPO), 1.31 Ϯ 1.53 (TSH-R) and 3.37 Ϯ 1.76 (NIS). In the patients with recurrent papillary carcinoma, the ratios were 1.7 Ϯ 1.56, 0.65 Ϯ 0.30, 0.71 Ϯ 0.40 and 3.25 Ϯ 1.82 respectively. The ratios of each product of the Tg, TPO, TSH-R and NIS mRNAs to b-actin mRNA in primary papillary thyroid carcinoma are shown in Fig. 3 . In all the patients, there was a positive correlation among the differentiation markers, Tg, TPO and NIS with respect to levels of expression (Fig. 4) . 
Relationship between the expression of differentiation markers and clinical characteristics in patients with primary papillary carcinoma (Table 3)
In the patients with primary papillary carcinoma, there was a significant correlation between the expression of each mRNA and the MACIS score only for the Tg gene (P < 0.05). There were no significant differences between other clinical data, including age, sex, tumour size and extrathyroidal invasion, and the levels of expression of the four differentiation markers.
Discussion
All the participants in this study expressed three differentiation markers, Tg, TPO and TSH-R. Among those with either primary or recurrent papillary carcinoma, eight did not express NIS mRNA. In a recent report, Arturi et al. observed a reduction in the NIS gene in papillary carcinoma (16) , whereas Saito et al. (15) reported that expression of the NIS gene was greater in papillary carcinomas than in adjacent normal thyroid tissues. However, clinically, the ability of normal thyrocytes to take up radioiodide is considered to be much greater than that of papillary thyroid (34) . In our previous studies (35, 36) , we reported that, in papillary carcinomas, those patients who showed heterogeneous distribution of TSH-R mRNA tended to be in advanced stages of the diseases. A significantly poorer prognostic score was also achieved by patients with papillary carcinomas having a weaker intensity of TSH-R protein than that of the adjacent normal thyroid. In this study, we investigated the correlation of these differentiation markers, including the NIS gene, and the relationship between their levels of expression and the clinical findings in patients with papillary carcinoma. As noted in our previous study (35) , expression of the TSH-R gene in the advanced stages of the disease was significantly lower than that in the early stages. However, in the correlation between the MACIS score and each gene, only Tg showed a significant correlation. Other investigators have reported a reduction in the differentiation markers in cases of papillary carcinoma with a high potential for malignancy (3, 37) . On the basis of our findings, with the exception of TSH-R mRNA, the NIS mRNA level significantly correlated with Tg and with TPO as classical differentiation markers of each other. However, the relationships with clinical stage and prognostic score varied among these differentiation markers.
Figure 4
Correlations among the differentiation markers. The ratio of each product of the Tg, TPO, TSH-R and NIS mRNAs to b-actin mRNA in all patients is shown in Fig. 3 . There was positive correlation among Tg, TPO and NIS with respect to the relationship of the expression of these differentiation markers in all the patients.
